Shenzhen Neptunus Bioengineering News

Haiwang Bio (000078): foreign Investment rating (FIR)

中盛在線Jul 13, 2020 00:00

Sea King Bio (000078): 2019Q4 Foreign Investment rating report (overseas Institution Investment rating C)

中盛在線Jan 10, 2020 00:00

Neptune Biotech (000078) interim report review: Continued performance is impressive, operating cash flow improved in Q2

廣證恆生Aug 27, 2018 00:00

Kaiwang Biotech (000078) Review of the Third Quarterly Report: Beautiful Performance and Strong M&A Execution

西南證券Oct 31, 2017 00:00

Deepin* Company* Haiwang Biotech (000078) Interim Report Comment: Accelerating Mergers and Acquisitions, Accelerating Expansion, Endogenous Outreach, Establishing a Rapid Growth Trend

中銀國際Aug 31, 2017 00:00

Deep*Company*Kaiwang Biotech (000078) In-depth Research: Epitaxial Acceleration Achieves Leapfrog Development to Build a Regional Distribution Leader

中銀國際Jul 30, 2017 00:00

Haiwang Bio (000078) comment report: the pharmaceutical business is expanding rapidly and many businesses are also being promoted.

銀河證券Jan 6, 2017 00:00

[China Galaxy] Haiwang Biological Review report: pharmaceutical business is expanding rapidly, and a number of businesses are also being promoted.

中國銀河Jan 4, 2017 00:00

Depth * Company * Sea King Biology (000078): continue to promote the growth of GPO procurement business performance without worry

中銀國際Aug 29, 2016 00:00

[bank of China International Securities] Haiwang Bio: continue to promote GPO procurement business, worry-free performance growth

中銀國際證券Aug 29, 2016 00:00

海王生物(000078)点评：流通、制造双核驱动下的医药巨头

財達證券Jun 22, 2016 00:00

【国信证券】海王生物:打造一致性评价平台,保障全药网持续推进

國信證券May 30, 2016 00:00

海王生物(000078)点评：打造一致性评价平台 保障全药网持续推进

國信證券May 30, 2016 00:00

【西南证券】海王生物:进军质子医疗,A股高精尖医疗设备稀缺标的

西南證券May 27, 2016 00:00

海王生物(000078)点评：进军质子医疗 A股高精尖医疗设备稀缺标的

西南證券May 27, 2016 00:00

海王生物(000078)调研简报：深圳GPO模式即将实施 海王为最佳收益标的

西南證券May 23, 2016 00:00

【西南证券】海王生物:深圳GPO模式即将实施,海王为最佳收益标的

西南證券May 23, 2016 00:00

海王生物(000078)季报点评：定增即将完成 业绩加速改善

國信證券Apr 29, 2016 00:00

【国信证券】海王生物:定增即将完成,业绩加速改善

國信證券Apr 29, 2016 00:00

海王生物(000078)年报点评：把握医改大机会 GPO延伸+外延驱动成长

國信證券Apr 28, 2016 00:00